Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational, Open Label Study With Direct Individual Benefit Assessing the Efficacy and Safety of Sofosdac® 400mg/60mg Tablets (400 mg Sofosbuvir and 60 mg of Daclatasvir) Treatment in Patients With Chronic Hepatitis C (HCV)

NCT05138523 is registered in ClinicalTrials.gov with Beker Laboratories as lead sponsor.

NCT NCT05138523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05138523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational, Open Label Study With Direct Individual Benefit Assessing the Efficacy and Safety of Sofosdac® 400mg/60mg Tablets (400 mg Sofosbuvir and 60 mg of Daclatasvir) Treatment in Patients With Chronic Hepatitis C (HCV)
Lead sponsor
Beker Laboratories
Phase
Observational
Overall status
Completed
Start date
November 21, 2019
Completion date
June 22, 2021
Enrollment
99 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c